Company

About

InflammX Therapeutics

InflammX Therapeutics

Tampa, Florida, United States

InflammX Therapeutics, Inc. is targeting inflammasome mediated and recycling inflammation, and providing a therapeutic effect to both eyes simultaneously. They have a pipeline focused on ophthalmic treatments and have submitted an IND amendment to enable clinical studies with orally dosed Xiflam, their NLRP3 inflammasome targeting program in retinal and kidney disease.

Oncogenuity

Oncogenuity

Bay Harbor Islands, Florida, United States

Oncogenuity is a biopharmaceutical company committed to developing and commercializing new treatments for genetically driven diseases. Our lead asset targets the KRAS mutation G12D, which plays a significant role in pancreatic and colorectal cancers, as well as other “untreatable” cancers of considerable unmet need. Our core technology focuses on the delivery of PNA’s (peptide nucleic acids). The PNA acts as a targeting sequence for gene-silencing. These targeting sequences are interchangeable, and we plan to aggressively pursue both oncology and non-oncology genetic mutations where gene silencing can be effective. We are a partner of Fortress Biotech, and we have an exclusive licensing agreement with Columbia University to develop oligomers (ONCOlogues) that attack genetically driven diseases at the DNA level.

Stuart Therapeutics

Stuart Therapeutics

Stuart, Florida, United States

Stuart Therapeutics (Stuart) is a clinical stage biopharmaceutical company focused on the development of a unique tissue reparative platform for eye diseases called PolyColTM (PolyCol). PolyCol is a family of synthesized polypeptide sequences that are specifically designed to repair damaged extracellular matrix (ECM) helical collagen. Helical collagen structures play an important role in healthy tissues and they are damaged in chronic and acute/traumatic disease processes and injuries. Stuart was founded in 2018 to champion a new approach to the treatment of chronic diseases. Each of our founders has been affected directly or indirectly by chronic eye disease, and we have a passion for the pursuit of new and effective solutions for these indications. Stuart’s areas of interest are Dry Eye Disease, Glaucoma, and Dry Age-Related Macular Degeneration.